Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
نویسندگان
چکیده
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK3475) and evaluation of immune-related response criteria (irRC) F Stephen Hodi, Antoni Ribas, Adil Daud, Omid Hamid, Caroline Robert, Richard Kefford, Wen-Jen Hwu, Tara C Gangadhar, Anthony M Joshua, Peter Hersey, Jeffrey Weber, Richard W Joseph, Hassane Zarour, Roxana Dronca, Linda Gammage, Darcy Hille, Dahai Xue, S Peter Kang, Patrick Chun, Scot W Ebbinghaus, Andrea Perrone, Jedd D Wolchok
منابع مشابه
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
PURPOSE We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). PATIENT...
متن کاملPhase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
PURPOSE This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors. EXPERIMENTAL DESIGN In a 3 + 3 dose escalation study, 10 patients received pembrolizumab 1, 3, or 10 mg/kg intravenously every 2 weeks until progression or intolerable toxicity. Seven additional patients...
متن کاملWHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing immunotherapy in oncology requires us to address the unique characteristics of immunotherapeutic ...
متن کاملPreclinical to clinical translation of anti-PD-1 blockade
Background Pembrolizumab (MK-3475), a humanized monoclonal IgG4 antibody against programmed death receptor 1 (PD-1), is currently being studied in clinical trials across more than 30 types of cancers. Immunotherapy with anti–PD-1 monoclonal antibodies such as pembrolizumab shows robust, durable anti-tumor activity in multiple indications including patients with advanced melanoma. A more complet...
متن کاملDeveloping a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
PURPOSE Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2014